We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dose-escalating Safety Study of ISIS 301012 in Homozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00280995
First Posted: January 24, 2006
Last Update Posted: August 3, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Ionis Pharmaceuticals, Inc.
Information provided by:
Kastle Therapeutics, LLC
  Purpose
The aim of this study is to assess the safety and efficacy of varying doses of ISIS 301012 as add-on therapy in subjects with Homozygous Familial Hypercholesterolemia

Condition Intervention Phase
Hypercholesterolemia, Familial Drug: ISIS 301012 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2, Open-Label, Dose Escalation Study to Assess the Safety and Efficacy of ISIS 301012 as Add-on Therapy in Homozygous Familial Hypercholesterolemia Subjects

Resource links provided by NLM:


Further study details as provided by Kastle Therapeutics, LLC:

Primary Outcome Measures:
  • Percent reduction in LDL-cholesterol from baseline [ Time Frame: Week 7 (Cohorts A-C), Week 15 (Cohort D) ]

Enrollment: 12
Study Start Date: January 2006
Study Completion Date: August 2007
Primary Completion Date: April 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cohort A
Loading doses followed by weekly maintenance doses
Drug: ISIS 301012
50 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
Experimental: Cohort B
Loading doses followed by weekly maintenance doses
Drug: ISIS 301012
100 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
Experimental: Cohort C
Loading doses followed by weekly maintenance doses
Drug: ISIS 301012
200 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
Experimental: Cohort D
Loading doses followed by extended weekly maintenance doses
Drug: ISIS 301012
300 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, 36, 43, 50, 57, 64,71, 78, and 85

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Weight ≥ 40 kg for Cohorts A, B, & C; Weight ≥ 50 kg for Cohort D
  • Diagnosis of Homozygous Familial Hypercholesterolemia.
  • Female must be non-pregnant and non-lactating.
  • On stable lipid lowering therapy for at least 4 weeks.
  • Lipid values that meet the pre-specified criteria.

Exclusion Criteria:

  • Subject had heart problems in the prior 6 months.
  • Subject has elevated ALT, AST, or CPK.
  • History of renal disease, liver disease, or malignancy.
  • Use of oral anticoagulants, unless the dose has been stable for 4 weeks
  • Have any other conditions, which in the opinion of the Investigator would make the subject unsuitable for enrollment, or could interfere with the subject participating in or completing the study.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00280995


Locations
United States, Illinois
Chicago, Illinois, United States, 60610
United States, New York
New York City, New York, United States, 10021
United States, North Carolina
Winston-Salem, North Carolina, United States, 27103
United States, Ohio
Cincinnati, Ohio, United States, 45229
United States, Texas
Houston, Texas, United States, 77030
Netherlands
Amsterdam, Netherlands, 1105 AZ
Sponsors and Collaborators
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.
Investigators
Study Director: Medical Monitor Genzyme, a Sanofi Company
  More Information

Responsible Party: Medical Monitor, Genzyme Coporation
ClinicalTrials.gov Identifier: NCT00280995     History of Changes
Other Study ID Numbers: 301012CS8
EudraCT No.: 2005-004796-38
First Submitted: January 20, 2006
First Posted: January 24, 2006
Last Update Posted: August 3, 2016
Last Verified: August 2016

Keywords provided by Kastle Therapeutics, LLC:
LDL-cholesterol
apoB-100
Homozygous Familial Hypercholesterolemia

Additional relevant MeSH terms:
Hypercholesterolemia
Hyperlipoproteinemia Type II
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases
Lipid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Hyperlipoproteinemias
Mipomersen
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents